---
schema_version: "secwatch.filing_event.v1"
accession: "0000926617-26-000045"
form_type: "8-K"
ticker: "AWHL"
cik: "0000926617"
company_name: "Aspira Women's Health Inc."
filed_at: "2026-06-17T20:28:08+00:00"
generated_at: "2026-06-17T20:29:07.472666+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Aspira Women's Health annual meeting results: all proposals approved

## Summary
- All six director nominees elected with ~95% of votes cast in favor (excluding broker non-votes).
- Advisory vote on executive compensation approved: 5.57M for, 0.51M against.
- Stock incentive plan amended to add 5M shares (total authorized 9.53M shares).
- Ratification of BDO USA as auditor for 2026 passed with 22.81M for, 0.02M against.

## SEC filing metadata
- accession: 0000926617-26-000045
- form_type: 8-K
- ticker: AWHL
- cik: 0000926617
- company_name: Aspira Women's Health Inc.
- filed_at: 2026-06-17T20:28:08+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/926617/000092661726000045/0000926617-26-000045-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/926617/000092661726000045/awhl-20260617x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000926617-26-000045
- JSON: https://secwatch.observer/filing/0000926617-26-000045.json
- Plain text: https://secwatch.observer/filing/0000926617-26-000045.txt

## Key facts
- Shareholder Votes
  Aspira Women's Health Inc. shareholders approved Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers at the 2026-06-17 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: Proposal 2: Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 20, 2026, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 5,568,783 505,829 276,305 16,569,699
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661726000045/0000926617-26-000045-index.htm
- Shareholder Votes
  Aspira Women's Health Inc. shareholders approved Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan at the 2026-06-17 meeting.
  - Proposal: equity plan
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: Proposal 3: Approval of an Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan The Company’s stockholders approved an amendment to the Company’s 2019 Stock Incentive Plan (the “2019 Plan”) to increase the number of shares of common stock authorized to be granted under the 2019 Plan by 5,000,000 shares so that a total of 9,532,818 shares of common stock are authorized to be granted under the 2019 Plan, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 5,654,497 624,233 72,187 16,569,699
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661726000045/0000926617-26-000045-index.htm
- Shareholder Votes
  Aspira Women's Health Inc. shareholders approved Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm at the 2026-06-17 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-17
  source text: Proposal 4: Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection of BDO USA, P.C. as the Company’s independent registered public accounting firm for the year ending December 31, 2026, as set forth below: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 22,810,174 15,244 95,198 0
  evidence_url: https://www.sec.gov/Archives/edgar/data/926617/000092661726000045/0000926617-26-000045-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.